Ritesh Rathore

Phase I Trial of Anti‐PSMA Designer CAR‐T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2‐T Cell Pharmacodynamics as a Determinant of Clinical Response

Richard P. Junghans, Qiangzhong Ma, Ritesh Rathore et al. · The Prostate · 2016 · 265 citations

Medicine, Immunology, Oncology +17

Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/<i>neu</i>

Howard Safran, David A. Iannitti, Ramesh K. Ramanathan et al. · Cancer Investigation · 2004 · 190 citations

Medicine, Oncology, Pharmacology +16

Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma

Howard Safran, Margaret M. Steinhoff, Shamlal Mangray et al. · American Journal of Clinical Oncology · 2001 · 162 citations

Medicine, Oncology, Pathology +14

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

Lawrence G. Lum, Archana Thakur, Zaid Al‐Kadhimi et al. · Clinical Cancer Research · 2015 · 108 citations · Full text

Medicine, Immunology, Oncology +14

Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers <i>In vitro</i> and in an Animal Model

Ursula Reusch, Magesh Sundaram, Pamela A. Davol et al. · Clinical Cancer Research · 2006 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17